Takeda Pharmaceutical Co Ltd ADR
$ 17.23
1.06%
21 Jul - close price
- Market Cap 54,449,222,000 USD
- Current Price $ 17.23
- High / Low $ 17.25 / 17.02
- Stock P/E N/A
- Book Value 14.47
- EPS -0.30
- Next Earning Report 2026-07-30
- Dividend Per Share $200.00
- Dividend Yield 3.6 %
- Next Dividend Date -
- ROA 0.03 %
- ROE -0.02 %
- 52 Week High 18.90
- 52 Week Low 12.78
About
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Analyst Target Price
$21.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-29 | 2025-10-30 | 2025-07-30 | 2025-06-25 | 2025-01-30 | 2024-10-31 | 2024-07-31 | 2024-05-09 | 2024-02-01 | 2023-10-26 | 2023-07-27 | 2023-05-11 |
| Reported EPS | 0.2099 | -0.0253 | 151 | -0.2276 | 0.0478 | 29.07 | 0.1923 | -0.0065 | 33.79 | -15.5 | 28.76 | 0.074 |
| Estimated EPS | None | 0.151 | 0.2006 | -0.166 | 0.63 | 87.45 | 0.1228 | -0.0142 | 0.1085 | 0.1441 | 18.62 | 0.0505 |
| Surprise | 0 | -0.1763 | 150.7994 | -0.0616 | -0.5822 | -58.38 | 0.0695 | 0.0077 | 33.6815 | -15.6441 | 10.14 | 0.0235 |
| Surprise Percentage | None% | -116.755% | 75174.1775% | -37.1084% | -92.4127% | -66.7581% | 56.5961% | 54.2254% | 31042.8571% | -10856.4192% | 54.4576% | 46.5347% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.41 |
| Currency | USD |
Previous Dividend Records
| Jul 2026 | Dec 2025 | Jul 2025 | Dec 2024 | Jul 2024 | Dec 2023 | Jul 2023 | Dec 2022 | Jul 2022 | Jul 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-07-06 | 2025-12-11 | 2025-07-07 | 2024-12-12 | 2024-07-08 | 2023-12-11 | 2023-07-10 | 2022-12-12 | 2022-07-11 | 2021-07-12 |
| Amount | $0.308273 | $0.322144 | $0.33901 | $0.326079 | $0.292214 | $0.319068 | $0.30996 | $0.329553 | $0.330062 | $0.406627 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TAK
2026-07-20 11:12:25
Novartis' Tafinlar and Takeda's Adcetris in combination with bendamustine have gained routine use on the NHS for rare blood cancers, benefiting approximately 200 patients annually. These drugs offer additional therapeutic options, particularly for cases where other treatments have failed, and align with the UK’s National Cancer Plan to improve access to new treatments and enhance patient support. The therapies provide personalized, mutation-specific approaches, allowing many patients to receive treatment at home.
2026-07-20 06:01:00
Takeda Pharmaceutical's dengue vaccine, QDENGA, has received approval from India's drug regulator, making it the first dengue vaccine to be approved in the country. The announcement was made by the company's Indian unit on Monday. This development marks a significant step in the fight against dengue fever in India.
2026-07-20 06:01:00
Takeda Pharmaceutical's dengue vaccine QDENGA has been approved by India's drug regulator, making it the first such vaccine cleared in the country. This two-dose vaccine is effective against all four dengue virus serotypes and is indicated for ages 4 to 60, with high efficacy rates against confirmed dengue cases and hospitalizations. The approval marks a significant step in combating the rapidly spreading mosquito-borne illness in India, where cases have risen sharply in the past two decades.
2026-07-19 20:10:03
Takeda has partnered with Insilico Medicine to leverage its Pharma.AI suite for early-stage drug discovery across various therapeutic areas. This collaboration involves significant upfront payments and potential milestones totaling around US$600 million, granting Takeda exclusive development and commercialization rights. The partnership highlights a growing trend in the pharmaceutical industry to utilize AI platforms to accelerate drug candidate identification and streamline R&D processes.
2026-07-18 13:09:32
Takeda Pharmaceutical Company reported strong FY2024 results with core revenue growth of 2.8% and a 4.9% increase in core operating profit at constant exchange rates, driven by growth and launch products. The company also announced an increased dividend of JPY 200 per share and outlined a broadly flat FY2205 guidance for core revenue, operating profit, and EPS. Efficiency programs and pipeline acceleration were highlighted as key drivers for future profitability and growth.
2026-07-18 10:40:09
Takeda Pharmaceutical (TSE:4502) remains in focus after releasing new Phase 3 data for its oral TYK2 inhibitor zasocitinib for moderate to severe plaque psoriasis and announcing plans for a US FDA filing. Despite shares seeing a solid run recently and sitting below the average analyst price target, the company is considered 10.7% undervalued with a fair value of around ¥6,136. This valuation anticipates moderation of VYVANSE generic erosion post-FY2025, allowing core growth products to drive recovery, though risks like generic competition and debt remain.
